This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MYOK MyoKardia (MYOK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MyoKardia Stock (NASDAQ:MYOK) 30 days 90 days 365 days Advanced Chart Get MyoKardia alerts:Sign Up Key Stats Today's Range$224.91▼$224.9150-Day Range$222.81▼$224.9152-Week Range$42.65▼$225.00VolumeN/AAverage Volume752,969 shsMarket Capitalization$11.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. Read More Receive MYOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter. Email Address MYOK Stock News HeadlinesFulcrum Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FULC | BenzingaMarch 27, 2025 | benzinga.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024November 13, 2024 | markets.businessinsider.comThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.... a consultant who's worked for the likes of J.P. Morgan and Citicorp... into the middle of the Utah desert with a film crew.Why? So he could lead an investigation into a radical new kind of energy that's so abundant, the Dept. of Energy says it could meet America's power needs for the next 2 million years. It's got nothing to do with wind, solar, nuclear, oil or gas.July 2 at 2:00 AM | Stansberry Research (Ad)Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide MoatNovember 12, 2024 | morningstar.comMHealthEx Raises $14M led by General Catalyst to Empower Patients and Health Systems to do more with Health DataOctober 21, 2024 | markets.businessinsider.comMavacamten Shows Promise in Heart Failure With Normal to Supranormal EFOctober 1, 2024 | msn.comBristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)September 27, 2024 | seekingalpha.comSepterna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development RolesSeptember 25, 2024 | finance.yahoo.comSee More Headlines MYOK Stock Analysis - Frequently Asked Questions How were MyoKardia's earnings last quarter? MyoKardia, Inc. (NASDAQ:MYOK) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.16. What other stocks do shareholders of MyoKardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that MyoKardia investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2020Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOK CIK1552451 Webwww.myokardia.com Phone650-741-0900FaxN/AEmployees318Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$276.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.99% Return on Assets-42.42% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$33.56 million Price / Sales357.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book25.59Miscellaneous Outstanding Shares53,323,000Free FloatN/AMarket Cap$11.99 billion OptionableOptionable Beta1.84 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MYOK) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyoKardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyoKardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.